Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that sales of drugs to treat hypertension in China will nearly double from $440 million in 2005 (approximately 4% of the U.S. market) to more than $800 million in 2010. According to the new Emerging Markets -- China report entitled Hypertension in China, this increase will result from a rapidly growing proportion of the population with hypertension and rising awareness of the disease, which will raise the diagnosis rates by 8%.
"Diagnosis rates for hypertension will rise from 33% in 2005 to 41% in 2010 in tandem with health education efforts lead by the government," said Nikhil Mehta, analyst at Decision Resources. "China has identified hypertension as a primary target in its first long-term national plan for chronic disease control and prevention. This urban reform toward community care has the potential to significantly boost disease awareness in cities."
Urban areas won't be the only focus. Access to basic medical care among the inhabitants of rural provinces should rise as the new rural cooperative medical scheme expands and provides wider, but still limited, reimbursement of diagnostic fees and treatment with the least expensive Western drugs.
Hypertension in China also finds that the migration from rural to urban China in the next ten years will expose more individuals to risk factors for hypertension, such as obesity. The burden of disease will grow disproportionately in cities as a consequence of urbanization.
This new report from Decision Resources assesses the commercial opportunity in the Chinese pharmaceutical market for hypertension based on population dynamics, economic development, disease epidemiology, and changing physicians' practices. Key elements of each report in our Emerging Markets -- China series include:
* Accurate sizing of the patient population with access to Western medicine * Projections for future patient populations based on trends in lifecycle, urbanization, and economic status * Current treatment patterns and drivers of choice * Physician-defined unmet needs in diagnosing and treating the disease * Disease-specific pricing and reimbursement environment * Key drivers of market growth About Emerging Markets - China
Emerging Markets - China is the first and only syndicated report series focusing on high-growth emerging markets with comprehensive disease-specific analysis. With these reports, biopharmaceutical companies can:
* More accurately assess their commercial opportunity for Western brands in China. * Understand the physician treatment patterns and drivers of choice in key urban areas based on primary research. * Gain a clear perspective from a 5-year, drug-level market forecast, which is broken out by multinational sales versus Chinese-based companies. About Decision Resources
Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
Web site: http://www.decisionresources.com/